(Q30226427)

11 June 2017

title

Evaluation of a virosomal H5N1 vaccine formulated with Matrix M™ adjuvant in a phase I clinical trial (English)

1 reference

11 June 2017

main subject

phase I clinical trial

0 references

1 reference

15

0 references

Maria Zambon

14

object named as

Maria Zambon

1 reference

11 June 2017

1

Rebecca J Cox

1 reference

11 June 2017

Gabriel Pedersen

2

1 reference

11 June 2017

Abdullah S Madhun

3

1 reference

11 June 2017

Signe Svindland

4

1 reference

11 June 2017

Marianne Sævik

5

1 reference

11 June 2017

Lucy Breakwell

6

1 reference

11 June 2017

Katja Hoschler

7

1 reference

11 June 2017

Marieke Willemsen

8

1 reference

11 June 2017

Laura Campitelli

9

1 reference

11 June 2017

Jane Kristin Nøstbakken

10

1 reference

11 June 2017

Gerrit Jan Weverling

11

1 reference

11 June 2017

Jaco Klap

12

1 reference

11 June 2017

Kenneth C McCullough

13

1 reference

11 June 2017

Haakon Sjursen

16

1 reference

11 June 2017

language of work or name

English

0 references

publication date

22 August 2011

1 reference

11 June 2017

number of pages

11

1 reference

based on heuristic

inferred from page(s)

published in

Vaccine

1 reference

11 June 2017

volume

29

1 reference

11 June 2017

issue

45

1 reference

11 June 2017

page(s)

8049-8059

1 reference

Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine.

11 June 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.08.042

Safety and antigenicity of non-adjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a randomised trial of two potential vaccines against H5N1 influenza.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.08.042

Trial of 2009 influenza A (H1N1) monovalent MF59-adjuvanted vaccine.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.08.042

Preparing for a possible pandemic: influenza A/H5N1 vaccine development.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.08.042

Vaccines for an influenza pandemic: scientific and political challenges.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.08.042

Confronting the avian influenza threat: vaccine development for a potential pandemic.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.08.042

Response to a monovalent 2009 influenza A (H1N1) vaccine.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.08.042

Relationship between physical and chemical properties of aluminum-containing adjuvants and immunopotentiation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.08.042

Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine: a randomised controlled trial.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.08.042

Cross-reactivity to highly pathogenic avian influenza H5N1 viruses after vaccination with nonadjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a potential priming strategy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.08.042

Boosting immunity to influenza H5N1 with MF59-adjuvanted H5N3 A/Duck/Singapore/97 vaccine in a primed human population

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.08.042

Effects of adjuvants on the safety and immunogenicity of an avian influenza H5N1 vaccine in adults

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.08.042

An adjuvanted, low-dose, pandemic influenza A (H5N1) vaccine candidate is safe, immunogenic, and induces cross-reactive immune responses in healthy adults.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.08.042

ISCOM technology-based Matrix M™ adjuvant: success in future vaccines relies on formulation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.08.042

ISCOMATRIX adjuvant for prophylactic and therapeutic vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.08.042

Influenza virosomes in vaccine development

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.08.042

Intramuscular Matrix-M-adjuvanted virosomal H5N1 vaccine induces high frequencies of multifunctional Th1 CD4+ cells and strong antibody responses in mice.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.08.042

Matrix-M adjuvanted virosomal H5N1 vaccine confers protection against lethal viral challenge in a murine model

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.08.042

Sialic acid receptor specificity on erythrocytes affects detection of antibody to avian influenza haemagglutinin.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.08.042

MF59-adjuvanted H5N1 vaccine induces immunologic memory and heterotypic antibody responses in non-elderly and elderly adults

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.08.042

Safety and immunogenicity of an inactivated split-virion influenza A/Vietnam/1194/2004 (H5N1) vaccine: phase I randomised trial.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.08.042

Safety and reactogenicity profile of an adjuvanted H5N1 pandemic candidate vaccine in adults within a phase III safety trial.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.08.042

Safety and immunogenicity of an inactivated adjuvanted whole-virion influenza A (H5N1) vaccine: a phase I randomised controlled trial.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.08.042

A clinical trial of a whole-virus H5N1 vaccine derived from cell culture.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.08.042

Safety and antigenicity of whole virus and subunit influenza A/Hong Kong/1073/99 (H9N2) vaccine in healthy adults: phase I randomised trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.08.042

Immunogenicity of a monovalent, aluminum-adjuvanted influenza whole virus vaccine for pandemic use.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.08.042

The virosome concept for influenza vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.08.042

Eleven years of Inflexal V-a virosomal adjuvanted influenza vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.08.042

Safety and immunogenicity of a recombinant hemagglutinin vaccine for H5 influenza in humans.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.08.042

Cross-protection against lethal H5N1 challenge in ferrets with an adjuvanted pandemic influenza vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.08.042

Measurement of neutralizing antibody responses against H5N1 clades in immunized mice and ferrets using pseudotypes expressing influenza hemagglutinin and neuraminidase

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.08.042

Safety and immunogenicity of a prototype adjuvanted inactivated split-virus influenza A (H5N1) vaccine in infants and children.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.08.042

Immunogenicity, safety, and cross-reactivity of an inactivated, adjuvanted, prototype pandemic influenza (H5N1) vaccine: a phase II, double-blind, randomized trial.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.08.042

Preclinical and clinical development of plant-made virus-like particle vaccine against avian H5N1 influenza

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.08.042

Correlates of Protection Against Influenza

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.08.042

Adjuvanted H5N1 vaccine induces early CD4+ T cell response that predicts long-term persistence of protective antibody levels

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.08.042

Safety and cross-reactive immunogenicity of candidate AS03-adjuvanted prepandemic H5N1 influenza vaccines: a randomized controlled phase 1/2 trial in adults

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.08.042

Detection of antibody to avian influenza A (H5N1) virus in human serum by using a combination of serologic assays.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.08.042

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/J.VACCINE.2011.08.042

1 reference

11 June 2017

1 reference